Ferretab comp capsules 152.1mg/0.5mg №10×3

Name:
Ferretab comp. caps. 152.1mg/0.5mg in bl. in pack. No. 10×3
Description:
Hard gelatin capsules, size 2, color: red, containing 3 reddish-brown mini-tablets and one yellow mini-tablet. Main active ingredient Ferrous fumarate + folic acid Release formCapsules Dosage Ferrous fumarate + folic acid Pharmacological action Ferretab comp. contains active substances: ferrous fumarate and folic acid in sustained release mini-tablets, which avoids high local concentrations of iron that can irritate the mucous membrane. This drug is intended to restore the normal level of iron and folic acid in the blood, due to the increased need for folic acid and iron during pregnancy. Thus, it prevents complications such as: anemia, miscarriage, bleeding, premature birth and impaired mental development of the child due to iron and folic acid deficiency. Indications for use For the treatment of latent iron deficiency and iron deficiency anemia with folic acid deficiency, especially during pregnancy. Dosage and administration Dosage Adults over 18 years old – For mild iron deficiency anemia and latent iron deficiency with folic acid deficiency or for the prevention of iron deficiency and folic acid deficiency: 1 capsule per day. – In severe iron and folic acid deficiency: 1 capsule 2-3 times a day. – During pregnancy, the maximum recommended dose is 2 capsules per day. Do not prescribe higher doses for a long time. Persons under 18 years old There are no indications for the use of Ferretab Comp. in persons under 18 years of age. How to use Capsules are taken without chewing, approximately 30 minutes before breakfast or other meals, drinking plenty of water. Duration of use Treatment should be continued for at least 4 weeks, maximum 12 weeks after normalization of serum iron and hemoglobin levels, 1 capsule per day. If you forget to take Ferretab Comp., take the missed capsule as soon as you remember. Take the next capsule at your usual time. Do not take a double dose to make up for a missed dose. Application during pregnancy and lactationCapsules Ferretaba comp. suitable for use during pregnancy and lactation. The need for iron during pregnancy and lactation increases exponentially and in most cases cannot be met by body stores or diet. Therefore, the iron level should be replenished in the second half of pregnancy in case of a decrease in laboratory values. In addition, the need for iron increases during lactation. Folic acid is commonly used to treat megaloblastic anemia during pregnancy. The need for folic acid increases significantly during pregnancy, and a deficiency leads to fetal damage. Studies in pregnant women have not shown an increase in the risk of fetal pathologies during the use of the drug. Research cannot rule out the possibility of harm to the fetus, but folic acid should nonetheless be used during pregnancy if clearly needed. Folic acid is excreted in the milk of lactating women. During lactation, the need for folic acid increases markedly, however, the amount present in milk is sufficient to meet the needs of the child, although an increase in the amount may be necessary if the child is low at birth, in the case of breastfeeding by a mother with a deficiency of folic acid (50 mcg per day) and in patients with infections or prolonged diarrhoea. It is unlikely that the use of Ferretab comp. may cause unwanted effects during pregnancy and lactation. Precautions To avoid the risk of iron overdose, special care should be taken when taking dietary or other supplements containing iron salts. Treatment of iron deficiency anemia in most cases gives good results, but despite this, it is extremely important to identify the cause of iron deficiency. The possible coloring of the stool black is irrelevant. It should be borne in mind that the detection of occult blood in the stool can be a false positive. Before carrying out such an analysis, taking capsules Ferretab comp. should be stopped for a few days. With the introduction of folic acid at a daily dosage of 1 mg or more in pernicious anemia, remission of hematological parameters may occur, while neurological manifestations will progress. Therefore, pernicious anemia should be ruled out before treatment with folic acid. Effective iron therapy should continue after the normalization of erythrocyte blood parameters for several (at least 4-12) weeks, until the iron deficiency is completely eliminated and intracellular iron depots are replenished. Monitoring the course of treatment: If required, the degree of iron deficiency, the effectiveness of treatment and the need for continued iron replacement is determined by the following parameters at an interval of 4 weeks: hemoglobin, the number and indicators of red blood cells (MCV, MCH), reticulocytes, serum iron levels, transferrin. Determination of serum ferritin allows assessing the state of intracellular iron depots; serum ferritin < 15 mcg/l indicates empty depots in the body. This medicinal product contains lactose. Patients with rare congenital galactose intolerance, congenital lactase deficiency or glucose-galactose malabsorption should not take this drug. Contained in Ferretab Comp. dyes E122 and E104 can cause allergic reactions. Interaction with other drugs With the simultaneous use of capsules Ferretab comp. with the following substances, the following therapeutic effects may occur: Interaction with Possible effects Antacids (aluminum, magnesium, calcium salts), calcium and magnesium dietary supplements, colstyramine, colestipol, calcium bromide lactobionate, caffeine (coffee and tea), milk (dairy products), sodium bicarbonate, iron binders such as phosphates, phytates, or oxalates Decreased iron levels Anticonvulsant drugs (eg, phenytoin, phenobarbital, pyrimidone) Decreased blood levels of anticonvulsant drugs due to folic acid intake and thus , under certain circumstances increased convulsive readiness Ascorbic acid Increased absorption of iron Quinolone antibiotics (e.g. ciprofloxacin, levofloxacin, norfloxacin, ofloxacin) Iron salts affect the resorption of quinolone antibiotics Chloramphenicol Increased breakdown of chloramphenicol, reduced iron action Fluorouracil or oral fluoropyrimidines (eg, capecitabine) Concomitant administration of high doses of folic acid has been shown to enhance the action and thus increase the (cyto-) toxicity of fluorouracil or oral fluoropyrimidines. This can lead, for example, to severe diarrhea. Folic acid antagonists (eg, chemotherapy drugs such as trimethoprim, proguanil, pyrimethamine, and cytotoxic drugs such as methotrexate) Co-inhibition of the action of levodopa, methyldopa has been noted when folic acid is taken at high doses. Iron salts reduce the resorption of levodopa and methyldopa. iron resorption (therefore should be taken on an empty stomach) Penicillamine Mutual decrease in blood levels (chelate formation) Tetracycline Decrease in tetracycline levels Thyroxine Iron salts reduce thyroxine resorption in patients receiving thyroxine replacement therapy. Tocopherol Reducing the action of tocopherol Zinc Reducing the level of zinc Contraindications - Hypersensitivity to the active ingredients or to any of the auxiliary components of the drug (see Composition); - Current status in diseases associated with impaired iron accumulation: hemochromatosis, hemosiderosis, chronic hemolysis; - Violations of iron absorption: sideroachretic anemia, thalassemia, lead anemia; - Hemoglobinopathies, hemolytic anemia, aplastic anemia, pernicious anemia, anemia not caused by iron and folic acid deficiency, disorders of the gastrointestinal tract. Composition Active substances: 1 capsule contains 152.10 mg of ferrous fumarate II (equivalent to Fe (II) 50 mg) and 0.50 mg of folic acid. Excipients: lactose monohydrate, polyacrylate dispersion 30%, colloidal anhydrous silicon dioxide, magnesium stearate, microcrystalline cellulose, azorubine (E 122), quinoline yellow (E 104), titanium dioxide (E 171), gelatin. Overdose After taking very high doses, iron toxicity can occur with the following symptoms: 1-6 hours after ingestion: stomach pain, vomiting, diarrhea with black stools, loss of consciousness, gastrointestinal bleeding, shock. 6-24 hours after ingestion: fever, leukocytosis, metabolic acidosis, bleeding disorders, liver and kidney damage. Treatment must be started immediately to prevent the absorption of large amounts of iron: - if the patient's condition allows, clean the stomach with emetic solutions and / or gastric lavage (1% sodium bicarbonate - to form insoluble iron carbonate). Further: the intake of raw eggs and milk can contribute to the complex formation of iron ions, which will reduce the absorption of iron through the gastrointestinal tract. - specific therapy for poisoning: deferoxamine (check the dose in the relevant instructions for specialists), - additional symptomatic shock therapy. Side effects Like all medicines, Ferretab Comp. may cause side effects, although not everybody gets them. The following adverse reactions have been registered. Rare (less than 1 person in 1000): allergic skin reactions - erythema, itching. Very rare (less than 1 person in 10,000): paroxysmal nocturnal hemoglobinuria, erythropoietic porphyria or tardive cutaneous porphyria, allergic reactions such as bronchospasm, nausea or anaphylactic shock. Frequency not known (frequency cannot be determined from the available data): feeling of fullness in the abdomen, colicky pain in the stomach, heartburn, vomiting, diarrhea or constipation. If you experience any adverse reactions, it is recommended that you consult your doctor. This recommendation applies to any possible adverse reactions, including those not listed in the instructions for use of the drug. You can also report adverse reactions to the adverse drug reactions (actions) information database, including reports of drug failures. By reporting adverse reactions, you help to get more information about the safety of the drug. Storage conditionsStore at a temperature not exceeding 25 °C. Store in a place protected from light. Keep out of the reach of children. Buy Ferretab comp capsules 152.1mg/0.5mg No. 10x3